Axsome Therapeutics Inc. (AXSM) 2024年年度报告「NASDAQ」.pdf

《Axsome Therapeutics Inc. (AXSM) 2024年年度报告「NASDAQ」.pdf》由会员分享，可在线阅读，更多相关《Axsome Therapeutics Inc. (AXSM) 2024年年度报告「NASDAQ」.pdf（193页珍藏版）》请在三个皮匠报告上搜索。

1、 Table of Contents UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549 FORM 10-KANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31,2024 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANG

2、E ACT OF 1934 For the transition period from _ to _ Commission File Number 001-37635 AXSOME THERAPEUTICS,INC.(Exact name of registrant as specified in its charter)Delaware(State or other jurisdiction ofincorporation or organization)45-4241907(I.R.S.EmployerIdentification No.)One World Trade Center22

3、nd FloorNew York,New York(Address of principal executive offices)10007(Zip Code)Registrants telephone number,including area code:(212)332-3241 Securities registered pursuant to Section 12(b)of the Act:Title of each class:Common Stock,Par Value$0.0001 Per Share(Title of Class)Trading Symbol(s)AXSMNam

4、e of Each Exchange on Which Registered The Nasdaq Global Market Securities registered pursuant to Section 12(g)of the Act:NoneIndicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes No Indicate by check mark if the registrant is not r

5、equired to file reports pursuant to Section 13 or Section 15(d)of the Act.Yes No Indicate by check mark whether the registrant:(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934 during the preceding 12 months(or for such shorter period that the

6、 registrant was required to file such reports),and(2)has been subject to such filing requirements for the past 90 days.Yes No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during